Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography

Journal of Virology

Volumn 88, Issue 21, 2014, Pages 12265-12275

  Dutta, Moumita ^a   Liu, Jun ^b   Roux, Kenneth H ^a   Taylor, Kenneth A ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 447 52D; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MACROMOLECULE; NEUTRALIZING ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ELECTRON TOMOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN MN); IMAGE PROCESSING; NONHUMAN; V3 LOOP; VIRION; VIRUS ENVELOPE; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS SPIKE; CHEMICAL STRUCTURE; CHEMISTRY; CRYOELECTRON MICROSCOPY; IMMUNOLOGY; MACROMOLECULE; ULTRASTRUCTURE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CRYOELECTRON MICROSCOPY; ELECTRON MICROSCOPE TOMOGRAPHY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; MACROMOLECULAR SUBSTANCES; MODELS, MOLECULAR;

EID: 84907963599     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01596-14     Document Type: Article

References (90)

1. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888. http://dx.doi.org/10.1126/science.280.5371.1884.
2. Doms RW, Moore JP. 2000. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151:F9-F14. http://dx.doi.org/10.1083/jcb.151.2.F9.
3. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360. http://dx.doi.org/10.1126/science.1070441.
4. Cohen J. 2003. Public health: AIDS vaccine trial produces disappointment and confusion. Science 299:1290-1291.
5. Lifson JD, Rossio JL, Piatak M, Jr, Bess J, Jr, Chertova E, Schneider DK, Coalter VJ, Poore B, Kiser RF, Imming RJ, Scarzello AJ, Henderson LE, Alvord WG, Hirsch VM, Benveniste RE, Arthur LO. 2004. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res. Hum. Retrovir. 20: 772-787. http://dx.doi.org/10.1089/0889222041524661.
6. Sekaly RP. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205:7-12. http://dx.doi.org/10.1084/jem.20072681.
7. Acharya P, Luongo TS, Matz J, Schmidt SD, Chuang GY, Georgiev I, Kessler P, Yang Y, Chames P, Martin L, Mascola. JR, Kwong PD. 2012. Structural definition of a novel CD4-induced epitope that is targeted by a single-headed immunoglobulin to effect broad and potent HIV neutralization. Retrovirology 9:346. http://dx.doi.org/10.1186/1742-4690-9-S2-P346.
8. Liu L, Cimbro R, Lusso P, Berger EA. 2011. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc. Natl. Acad. Sci. U. S. A. 108:20148-20153. http://dx.doi.org/10.1073/pnas.1104840108.
9. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
10. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, Regoes RR, Gunthard HF, Trkola A. 2011. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J. Exp. Med. 208:1419-1433. http: //dx.doi.org/10.1084/jem.20110196.
11. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
12. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905. http://dx.doi.org/10.1128/JVI.75.22.10892-v10905.2001.
13. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
14. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027. http://dx.doi.org/10.1126 /science.7973652.
15. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
16. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O' Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
17. Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, Wolf H. 1987 Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J. Virol. 61:570-578.
18. Hoxie JA. 2010. Toward an antibody-based HIV-1 vaccine. Annu. Rev.Med.61:135-152.http://dx.doi.org/10.1146/annurev.med.60.042507. 164323.
19. Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW. 2007. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 3:e117. http://dx.doi.org/10.1371/journal.ppat.0030117.
20. Zolla-Pazner S, Cardozo T. 2010. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 10:527-535.
21. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P. 1990. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249:932-935. http://dx.doi.org/10.1126/science.2392685.
22. Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S. 2004. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J. Virol. 78:2394-2404. http://dx.doi.org/10.1128/JVI.78.5.2394-2404.2004.
23. Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S. 2010. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One 5:e10254. http://dx.doi.org/10.1371/journal.pone.0010254.
24. Schweighardt B, Liu Y, Huang W, Chappey C, Lie YS, Petropoulos CJ, Wrin T. 2007. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J. Acquir. Immune Defic. Syndr. 46:1-11.
25. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005 Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125. http://dx.doi.org/10.1128/JVI.79.16.10108-10125.2005.
26. Mascola JR, D' Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79:10103-10107. http://dx.doi.org/10.1128/JVI.79.16.10103-10107.2005.
27. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, Wyatt R, Sodroski J. 1997. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol. 71:9808-9812.
28. Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM. 2009. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J. Virol. 83:1240-1259. http://dx.doi.org/10.1128/JVI.01743-08.
29. Johnson WE, Morgan J, Reitter J, Puffer BA, Czajak S, Doms RW, Desrosiers RC. 2002. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J. Virol. 76:2075-2086. http://dx.doi.org/10.1128/jvi.76.5.2075-2086.2002.
30. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J. 2001. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 75:3435-3443. http://dx.doi.org/10.1128 /JVI.75.7.3435-3443.2001.
31. Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, Zolla-Pazner S, Kayman SC. 2005. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade A and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J. Virol. 79:780-790. http://dx.doi.org/10.1128/JVI.79.2.780-790.2005.
32. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769. http://dx.doi.org/10.1146 /annurev.immunol.24.021605.090557.
33. Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, Burke B, Cheng-Mayer C, Stamatatos L. 2005. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J. Virol. 79:9069-9080 http://dx.doi.org/10.1128/JVI.79.14.9069-9080.2005.
34. Stamatatos L, Cheng-Mayer C. 1998. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 72:7840-7845.
35. Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE. 2005. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J. Virol. 79:6957-6968. http://dx.doi.org/10.1128/JVI.79.11.6957-6968.2005.
36. Nyambi PN, Gorny MK, Bastiani L, van der Groen G, Williams C, Zolla-Pazner S. 1998. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J. Virol. 72:9384-9391.
37. Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S. 2002 Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76:9035-9045. http://dx.doi.org/10.1128/JVI.76.18.9035-9045.2002.
38. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841. http://dx.doi.org/10.1038/nature03327.
39. Chen X, Lu M, Poon BK, Wang Q, Ma J. 2009. Structural improvement of unliganded simian immunodeficiency virus gp120 core by normalmode-based X-ray crystallographic refinement. Acta Crystallogr. D Biol. Crystallogr. 65:339-347. http://dx.doi.org/10.1107/S0907444909003539.
40. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. http://dx.doi.org/10.1038/31405.
41. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD. 2007. Structures of the CCR5 N terminus and of a tyrosinesulfated antibody with HIV-1 gp120 and CD4. Science 317:1930-1934. http://dx.doi.org/10.1126/science.1145373.
42. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737. http://dx.doi.org/10.1038/nature05580.
43. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. 2005 Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028 http://dx.doi.org/10.1126/science.1118398.
44. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, Kong L, Kwon YD, Stuckey J, Zhou T, Robinson JE, Schief WR, Sodroski J, Wyatt R, Kwong PD. 2010. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U. S. A. 107:1166-1171. http://dx.doi.org/10.1073/pnas.0911004107.
45. Zhu P, Liu J, Bess J, Jr, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852. http://dx.doi.org/10.1038/nature04817.
46. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD. 2006. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog. 2:e83. http://dx.doi.org/10.1371 /journal.ppat.0020083.
47. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-113 http://dx.doi.org/10.1038/nature07159.
48. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S. 2010. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 6:e1001249. http://dx.doi.org/10.1371 /journal.ppat.1001249.
49. Hu G, Liu J, Taylor KA, Roux KH. 2011. Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J. Virol. 85: 2741-2750. http://dx.doi.org/10.1128/JVI.01612-10.
50. White TA, Bartesaghi A, Borgnia MJ, de la Cruz MJ, Nandwani R, Hoxie JA, Bess JW, Lifson JD, Milne JL, Subramaniam S. 2011. Threedimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. J. Virol. 85:12114-12123. http://dx.doi.org/10.1128/JVI.05297-11.
51. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramanian S. 2011. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U. S. A. 108:11440-11445. http://dx.doi.org/10.1073/pnas.1101414108.
52. Chertova E, Crise BJ, Morcock DR, Bess JW, Jr, Henderson LE, Lifson JD. 2003. Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins. Curr. Mol. Med. 3:265-272. http://dx.doi.org/10.2174 /1566524033479889.
53. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW, Jr, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, Arthur LO, Henderson LE, Lifson JD. 1998. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:7992-8001.
54. Winkler H, Taylor KA. 2006. Accurate marker-free alignment with simultaneous geometry determination and reconstruction of tilt series in electron tomography. Ultramicroscopy 106:240-254. http://dx.doi.org /10.1016/j.ultramic.2005.07.007.
55. Winkler H, Zhu P, Liu J, Ye F, Roux KH, Taylor KA. 2009. Tomographic subvolume alignment and subvolume classification applied to myosinVand SIV envelope spikes. J. Struct. Biol. 165:64-77. http://dx.doi.org/10.1016/j.jsb.2008.10.004.
56. Winkler H, Taylor KA. 1999. Multivariate statistical analysis of threedimensional cross-bridge motifs in insect flight muscle. Ultramicroscopy 77:141-152. http://dx.doi.org/10.1016/S0304-3991(99)00035-2.
57. Tang G, Peng L, Baldwin PR, Mann DS, Jiang W, Rees I, Ludtke SJ. 2007 EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157:38-46. http://dx.doi.org/10.1016/j.jsb.2006.05.009.
58. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. 2004. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 12:193-204. http://dx.doi.org /10.1016/j.str.2004.01.003.
59. Tama F, Miyashita O, Brooks CL, III. 2004. Normal mode based flexible fitting of high-resolution structure into low-resolution experimental data from cryo-EM. J. Struct. Biol. 147:315-326. http://dx.doi.org/10.1016/j.jsb.2004.03.002.
60. Feig M, Karanicolas J, Brooks CL, III. 2004. MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. J. Mol. Graph Model 22:377-395.
61. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612. http: //dx.doi.org/10.1002/jcc.20084.
62. Roux KH, Taylor KA. 2007. AIDS virus envelope spike structure. Curr. Opin. Struct. Biol. 17:244-252. http://dx.doi.org/10.1016/j.sbi.2007.03.008.
63. Mao Y, Wang L, Gu C, Herschhorn A, Xiang SH, Haim H, Yang X, Sodroski J. 2012. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat. Struct. Mol. Biol. 19:893-899. http: //dx.doi.org/10.1038/nsmb.2351.
64. Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, Frank GA, Sapiro G, Milne JL, Subramaniam S. 2012. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 8:e1002797. http://dx.doi.org/10.1371/journal.ppat.1002797.
65. Cormier EG, Dragic T. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76:8953-8957. http://dx.doi.org/10.1128/JVI.76.17.8953-8957.2002.
66. Spear GT, Takefman DM, Sharpe S, Ghassemi M, Zolla-Pazner S. 1994. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 204:609-615 http://dx.doi.org/10.1006/viro.1994.1575.
67. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD. 1989. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. U. S. A. 86:6768-6772. http://dx.doi.org/10.1073/pnas.86.17.6768.
68. Swetnam J, Shmelkov E, Zolla-Pazner S, Cardozo T. 2010. Comparative magnitude of cross-strain conservation of HIV variable loop neutralizationepitopes. PLoSOne5:e15994.http://dx.doi.org/10.1371/journal.pone. 0015994.
69. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. 2012. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U. S. A. 109:5663-5668. http://dx.doi.org/10.1073 /pnas.1112391109.
70. Xiang SH, Finzi A, Pacheco B, Alexander K, Yuan W, Rizzuto C, Huang CC, Kwong PD, Sodroski J. 2010. A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J. Virol. 84:3147-3161. http://dx.doi.org/10.1128/JVI.02587-09.
71. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, Zolla-Pazner S. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
72. Gorny MK, Xu JY, Karwowska S, Buchbinder A, Zolla-Pazner S. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635-643.
73. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. 2004 Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252. http://dx.doi.org/10.1128/JVI.78.23.13232-13252.2004.
74. Almond D, Kimura T, Kong X, Swetnam J, Zolla-Pazner S, Cardozo T. 2010 Structural conservation predominates over sequence variability in the crown of HIV type 1' s V3 loop. AIDS Res. Hum. Retrovir. 26:717-723. http://dx.doi.org/10.1089/aid.2009.0254.
75. Keller PM, Arnold BA, Shaw AR, Tolman RL, Van Middlesworth F, Bondy S, Rusiecki VK, Koenig S, Zolla-Pazner S, Conard P. 1993. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology 193:709-716. http://dx.doi.org/10.1006 /viro.1993.1179.
76. Rees WA, Keller RW, Vesenka JP, Yang G, Bustamante C. 1993. Evidence of DNA bending in transcription complexes imaged by scanning force microscopy. Science 260:1646-1649. http://dx.doi.org/10.1126/science.8503010.
77. Burke V, Williams C, Sukumaran M, Kim SS, Li H, Wang XH, Gorny MK, Zolla-Pazner S, Kong XP. 2009. Structural basis of the crossreactivity of genetically related human anti-HIV-1 MAbs: implications for design of V3-based immunogens. Structure 17:1538-1546. http://dx.doi.org/10.1016/j.str.2009.09.012.
78. Conley AJ, Conard P, Bondy S, Dolan CA, Hannah J, Leanza WJ, Marburg S, Rivetna M, Rusiecki VK, Sugg EE. 1994. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens. Vaccine 12:445-451.
79. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, Zolla-Pazner S, Kong XP. 2010. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat. Struct. Mol. Biol. 17:955-961. http://dx.doi.org/10.1038/nsmb.1861.
80. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452. http://dx.doi.org/10.1128/JVI.02108-09.
81. VanCott TC, Bethke FR, Polonis VR, Gorny MK, Zolla-Pazner S, Redfield RR, Birx DL. 1994. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153:449-459.
82. Zhu P, Chertova E, Bess J, Jr, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH. 2003. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl. Acad. Sci. U. S. A. 100:15812-15817. http://dx.doi.org/10.1073/pnas.2634931100.
83. Zhu P, Winkler H, Chertova E, Taylor KA, Roux KH. 2008. Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripodlike legs. PLoS Pathog. 4:e1000203. http://dx.doi.org/10.1371/journal.ppat.1000203.
84. Chojnacki J, Staudt T, Glass B, Bingen P, Engelhardt J, Anders M, Schneider J, Muller B, Hell SW, Krausslich HG. 2012. Maturationdependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science 338:524-528. http://dx.doi.org/10.1126 /science.1226359.
85. Chertova E, Bess JW, Jr, Crise BJ, Sowder IR, Schaden TM, Hilburn JM, Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:5315-5325. http://dx.doi.org/10.1128/JVI.76.11.5315-5325.2002.
86. Klein JS, Bjorkman PJ. 2010. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 6:e1000908. http://dx.doi.org/10.1371/journal.ppat.1000908.
87. Kwong PD, Wilson IA. 2009. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat. Immunol. 10:573-578. http://dx.doi.org/10.1038/ni.1746.
88. Dhillon AK, Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. 2008. Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set. Acta Crystallogr. D Biol. Crystallogr. D. 64:792-802. http://dx.doi.org/10.1107 /S0907444908013978.
89. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103. http://dx.doi.org /10.1126/science.1213256.
90. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA. 2013. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20:796-803. http://dx.doi.org/10.1038/nsmb.2594.